Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
Article 2013 en
Authors
DZ
Dick de Zeeuw
TA
Tadao Akizawa
PA
Paul Audhya
Abstract
1 min read
Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes. A higher rate of cardiovascular events with bardoxolone methyl than with placebo prompted termination of the trial. (Funded by Reata Pharmaceuticals; BEACON ClinicalTrials.gov number, NCT01351675.).
Scott D. Solomon, Hajime Uno, Eldrin F. Lewis, Kai‐Uwe Eckardt, Julie Lin, Emmanuel A. Burdmann, Dick de Zeeuw, Peter Ivanovich, Andrew S. Levey, Patrick S. Parfrey, Giuseppe Remuzzi, Ajay Singh, Robert D. Toto, Fannie Huang, Jérôme Rossert, John J.V. McMurray, Marc A. Pfeffer
Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina, John B. Buse, Juliana C.N. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo Maggioni, Steven P. Marso, Peter Öhman, Neha J. Pagidipati, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez
Marc A. Pfeffer, Emmanuel A. Burdmann, Chao Yin Chen, Mark E. Cooper, Dick de Zeeuw, Kai-Uwe Eckardt, Jan Feyzi, Peter Ivanovich, Reshma Kewalramani, Andrew S. Levey, Eldrin F. Lewis, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans Henrik Parving, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.